This is such huge news. Today marks a momentous change in the way we view treatment for CF. The first drug ever to target the underlying problem in CF has been approved by the FDA. And while it doesn't address our specific type of mutation, it gives enormous hope as a similar drug is in the works.
FDA Approves Kalydeco (VX-770) — First Drug That Targets the Underlying Cause of CF - CFF